S'abonner

Cancer-associated fibroblasts (CAFs) and plaque-associated fibroblasts (PAFs): Unraveling the cellular crossroads of atherosclerosis and cancer - 14/06/25

Doi : 10.1016/j.biopha.2025.118145 
Gavino Faa a, b, 1, Pina Ziranu c, , 1 , Andrea Pretta c, Flaviana Cau a, Massimo Castagnola d, Dario Spanu c, Giorgio Saba c, Alessandra Pia D’Agata c, Ekta Tiwari e, Jasjit S. Suri f, g, h, i, j, Mario Scartozzi c, 2, Luca Saba k, 2
a Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy 
b Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, USA 
c Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari 09042, Italy 
d Laboratory of Proteomics, Centro Europeo di Ricerca sul Cervello, IRCCS Fondazione Santa Lucia, Rome, Italy 
e Department of Innovation. Global Biomedical Technologies, Inc., Roseville, CA 95661, USA 
f Department of ECE, Idaho State University, Pocatello, ID, 83209, USA 
g Department of CE, Graphics Era Deemed to be University, Dehradun 248002, India 
h University Center for Research & Development, Chandigarh University, Mohali, India 
i Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, INDIA 
j Stroke Diagnostic and Monitoring Division, AtheroPoint, Roseville, CA 95661, USA 
k Department of Medical Sciences and Public Health, Unit of Radiology, University fo Cagliari, Cagliari, Italy 

Correspondence to: Medical Oncology Unit, University Hospital and University of Cagliari, SS 554 km 4500 Bivio per Sestu, Monserrato, Cagliari 09042, Italy.Medical Oncology Unit, University Hospital and University of CagliariSS 554 km 4500 Bivio per Sestu, MonserratoCagliari09042Italy

Abstract

Atherosclerosis is a complex process involving various cells and molecules within the atherosclerotic plaque. Recent evidence suggests that plaque-associated fibroblasts (PAFs), also known as atherosclerosis-associated fibroblasts (AAFs), might play a significant role in the development and progression of the disease. The microenvironment of the atherosclerotic plaque, resembling the tumor microenvironment (TME), includes various cellular populations like plaque-associated macrophages (PAMs), plaque-associated neutrophils (PANs), vascular smooth muscle cells (VSMCs), myeloid-derived suppressor cells (MDSCs), and PAFs. Similar to cancer-associated fibroblasts (CAFs) in tumors, PAFs exhibits a wide range of characteristics and functions. Their interactions with endothelial cells, smooth muscle cells, and other stromal cells, including adventitial fibroblast precursors, significantly influence atherosclerosis progression. Moreover, the ability of PAFs to express various markers such as alpha-SMA, Desmin, VEGF, and GFAP, highlights their diverse origins from different precursor cells, including vascular smooth muscle cells, endothelial cells, glial cells of the enteric nervous system, adventitial fibroblast precursors, as well as resident and circulating fibrocytes. This article explores the molecular interactions between PAFs, cells associated with atherosclerosis, and other stromal cells. It further examines the role of PAFs in the development and progression of atherosclerosis, and compares their features with those of CAFs. The research suggests that studying tumor-associated fibroblasts can help understand fibroblast subpopulations in atherosclerotic plaque. Identifying specific subpopulations could provide new insight into atherosclerosis complexity and lead to the development of innovative drugs for medical intervention.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

In brief: Atherosclerosis is a complex process that involves various cells and molecules within the atherosclerotic plaque. Recent research suggests that plaque-associated fibroblasts (PAFs) play a significant role in the development and progression of atherosclerosis. Similarly, cancer-associated fibroblasts (CAFs) are crucial in tumor growth, progression, and drug resistance.

This article explores the emerging role of PAFs in the development and progression of atherosclerosis. It also compares the microenvironment of the atherosclerotic plaque to that of cancer, highlighting potentially shared characteristics. Understanding the similarities, differences, and shared pathways between atherosclerosis and cancer, such as inflammation, cellular metabolism, and immune regulation, could offer new therapeutic approaches and significantly improve patient outcomes.


In brief: Atherosclerosis is a complex process that involves various cells and molecules within the atherosclerotic plaque. Recent research suggests that plaque-associated fibroblasts (PAFs) play a significant role in the development and progression of atherosclerosis. Similarly, cancer-associated fibroblasts (CAFs) are crucial in tumor growth, progression, and drug resistance.This article explores the emerging role of PAFs in the development and progression of atherosclerosis. It also compares the microenvironment of the atherosclerotic plaque to that of cancer, highlighting potentially shared characteristics. Understanding the similarities, differences, and shared pathways between atherosclerosis and cancer, such as inflammation, cellular metabolism, and immune regulation, could offer new therapeutic approaches and significantly improve patient outcomes.

Le texte complet de cet article est disponible en PDF.

Highlights

Cancer-related fibroblasts are crucial in tumor growth, progression, and drug resistance.
Plaque-associated fibroblasts promote atherosclerosis development and progression.
The atherosclerotic plaque shares similarities with the cancer cells.
The comparison of CAFs and PAFs can reveal potential therapeutic targets.
Identifying shared pathways between atherosclerosis and cancer could offer new treatment options.

Le texte complet de cet article est disponible en PDF.

Abbreviations : PAFs, AAFs, TME, PAMs, PANs, VSMCs, MDSCs, CAFs, Alpha-SMA, VEGF, GFAP, ECM, MMPs, PDGF, SCF, PDGF-D, TGF-β, FAP, FAP, FSP-1, TCGA, FGF, CXCL5, IGF, ADAM, β-FGF, BFGF, SDF-1, PDGFRα, GREM1, ISLR, BMP, L1CAM, LDLs, EndMT, Sca1, MMT, AIT, PIT, PME, DKK1, IPH, BMAL1, FSP1;, COL1A1, DCN, MYOCD, ACTA-2, MyH11, KLF4, CNN1, EMT, Tregs, IL-6, TNF-α

Keywords : Fibroblasts, Cancer-associated fibroblasts, Plaque-associated fibroblasts, Cancer, Atherosclerosis


Plan


© 2025  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 188

Article 118145- juillet 2025 Retour au numéro
Article précédent Article précédent
  • Doxycycline: An essential tool for Alzheimer’s disease
  • Gianluigi Forloni
| Article suivant Article suivant
  • Macrophage immunometabolism dysregulation and inflammatory disorders
  • Karen Pomeyie, Francis Abrokwah, Daniel Boison, Benjamin Amoani, Foster Kyei, Cynthia A. Adinortey, Prince Amoah Barnie

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.